ABC | Volume 114, Nº2, Fevereiro 2020

Atualização Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020 Arq Bras Cardiol. 2020; 114(2):325-429 tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58(7):740–8. 309. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasivemeasures of coronary flow reserve. Circulation. 2011;124(20):2215–24. 310. Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its associationwith clinical outcomes. Eur Heart J Cardiovasc Imaging. 2015;16(8):900–9. 311. Cecchi F, Olivotto I, Gistri R., Lorenzoni R., Chiriatti G., Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027-35. 312. McArdle BA, Davies RA, Chen L, Small GR, Ruddy TD, Dwivedi G, et al. Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant. Circ Cardiovasc Imaging. 2014;7(6):930–7. 313. Ito Y, Katoh C, Noriyasu K, Kuge Y, Furuyama H, Morita K, et al. Estimation of myocardial blood flowandmyocardial flow reserve by 99m-technetium sestamibi imaging: comparison with the results of 15 H2OPET. Eur J Nucl Med Mol Imaging. 2003;30(2):281-7. 314. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM. Long- termprognostic value of 13N-ammoniamyocardial perfusion PET: added value of coronary flow reserve. J Am Coll Cardiol. 2009;54(2):150-6. 315. Wells RG, Timmins R, Klein R, Lockwood J, Marvin B, deKemp RA,et al. Dynamic SPECT measurement of absolute myocardial blood flow in a porcine model. J Nucl Med. 2014;55(10):1685-91. 316. Ben Bouallègue F, Roubille F, Lattuca B, Cung TT, Macia JC, Gervasoni R, et al. SPECT myocardial perfusion reserve in patients with multivessel coronary disease: correlation with angiographic findings and invasive fractional flow reservemeasurements. J Nucl MedOff Publ Soc Nucl Med. 2015;56(11):1712–7. 317. Einstein, AJ, Pascual TN, Mercuri M, Karthikeyan G, Vitola JV, Mahmarian JJ, et al; Incaps Investigators group. Current worldwide nuclear cardiology practicesandradiationexposure:Results fromthe65country IAEAnuclear cardiology protocols. Eur Heart J. 2015;36(26):1689-96. 318. Vitola JV, Mut F, Alexánderson E, Pascual TN, Mercuri M, Karthikeyan G, et al; INCAPS Investigators. Opportunities for improvement on current nuclear cardiology practices and radiation exposure in Latin America: Findings from the 65-country IAEA Nuclear Cardiology Protocols Cross- sectional Study (INCAPS). J Nucl Cardiol. 2017;24(3):851-9. 319. Mastrocola LE, Alves FB, Lopes RW. Exames de imagem e risco da exposição às radiações. conceitos fundamentais. Rev DERC. 2012;18(2):44-5. 320. Albuquerque AS, Mastrocola LE. Radiação e exames diagnósticos: qual o risco real ? Rev Soc Cardiol Estado de São Paulo 2017;27(2):82-7. 321. Lima R, Peclat T, Soares T, Ferreira C, Souza AC, Camargo G. Comparison of the prognostic value of myocardial perfusion Imaging using a CZT- SPECT camera with a conventional anger camera. J Nucl Cardiol 2017;24(1):245-51. 322. Chirumamilla A, Travin MI. Cardiac applications of 123I-mIBG imaging. Semin Nucl Med 2011; 41(5):374-87. 323. Carrió I: Cardiac neurotransmission imaging. J Nucl Med 2001; 42(7):1062-76. 324. Petretta M, Pellegrino T, Cuocolo A. Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: implications of endpoint selection and quantitative analysis on clinical decisions. Eur J Nucl Med Mol Imaging 2014; 41(9):1663-5. 325. Gaudino M, Giordano A, Santarelli P, Alessandrini F, Nori SL, Trani C, et al. Immunohistochemical-scintigraphic correlation of sympathetic cardiac innervation in postischemic left ventricular aneurysms. J Nucl Cardiol 2002;9(6):601-7. 326. Stiles S. FDA Approves Heart Sympathetic Activity Imaging Agent for HF Evaluation. [online] Emedicine. medscape.com. [Cited in 2013 Feb 10]. Available from: https://www.medscape.com/viewarticle/791544. 327. Angelidis G, Giamouzis G, Karagiannis G, Butler J, Tsougos L, Valotassiou V, et al. SPECT and PET in ischemic heart failure. Heart Fail Rev. 2017;22(2):243-61. 328. Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANMCardiovascular Committee and the EuropeanCouncil of Nuclear Cardiology. Eur J Nucl MedMol Imaging. 2010;37(9):1802–12. 329. Rocha ET, Alves WEFM, Verschure DO, Verbene HJ. Uso do 123I-MIBG cardíaco na rotina clínica: a necessidade de padronizar. Int J Cardiovasc Sci. 2017;30(6):533-41. 330. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. J Nucl Cardiol. 2016;23(3):606-39. 331. Travin MI. Current clinical applications and next steps for cardiac innervation imaging. Curr Cardiol Rep. 2017;19(1):1. 332. Morozumi T, Kusuoka H, Fukuchi K, Tani A, Uehara T, Matsuda S, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38(1):49–52. 333. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, andQT dispersion. J AmColl Cardiol. 2009;53(5):426–35. 334. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-termprognosis in heart failure. JACC Cardiovasc Imaging. 2013;6(7):772–84. 335. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29(9):1147–59. 336. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008; 35(3):535–46. 337. JacobsonAF,SeniorR,CerqueiraMD,WongND,ThomasGS,LopezVA,et al. Myocardial iodine-123metaiodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol. 2010;55(20):2212–21. 338. Nakajima K, Nakata T. Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan. J Nucl Med 2015; 56(Suppl 4):11S–9. 339. JCS Joint Working Group. Guidelines for Clinical Use of Cardiac Nuclear Medicine (JCS 2010): digest version. Circ J. 2012;76(3):761-7. 340. Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, et al: Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin- converting enzyme inhibitor therapy. J Nucl Med. 1999; 40(2):217-23. 341. Matsuo Y, Kasama S, Toyama T, Funada R, Takama N, Koitabashi N, et al. Comparative effects of long-acting and short-acting loop diuretics on cardiac sympathetic nerve activity in patients with chronic heart failure. Open Heart. 2016;3(1):e000276. 342. Nishioka SA, Martinelli FilhoM, Brandão SC, Giorgi MC, VieiraML, Costa R, et al. Cardiac sympathetic activity pre and post resynchronization 425